Cite
MLA Citation
Patrick Schöffski et al.. “Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies.” Journal for immunotherapy of cancer, vol. 10, no. 2, 2022, p. . http://access.bl.uk/ark:/81055/vdc_100151273983.0x000006